Financial Data and Key Metrics Changes - For Q1 fiscal 2026, the company reported revenues of $158.3 million, an increase of 14% compared to the prior year quarter, driven by growth in entertainment offerings and higher food, beverage, and merchandise revenues [10][11] - Adjusted operating income for the first quarter was $7.1 million, an increase of $5.2 million year-over-year, primarily due to increased revenues, partially offset by higher SG&A and direct operating expenses [11] - The company had $30 million of unrestricted cash and a total debt balance of $622 million as of September 30, 2025 [11] Business Line Data and Key Metrics Changes - The company welcomed over 900,000 guests across 140 events during the quarter, setting a new record for the number of concerts in any quarter at the Garden [4][5] - Food and beverage per caps at concerts increased, while per caps at theaters decreased compared to the prior year, attributed to the mix of events [5] - The Christmas Spectacular is set to have 215 shows this year, up from 200 last year, with advanced ticket sales pacing ahead of the previous year [7][8] Market Data and Key Metrics Changes - The company is seeing strong demand for the Christmas Spectacular, expecting to host over 1 million guests this holiday season, with advanced ticket revenues pacing up double digits compared to last year [17][18] - Concert bookings are on track to exceed last year's total, with nearly 85% of the concert booking goal achieved for the year [21][22] Company Strategy and Development Direction - The company is focused on capital allocation priorities, including maintaining a strong balance sheet, pursuing compelling opportunities, and returning capital to shareholders [28][29] - The internal sales team for marketing partnerships is largely in place, aiming to capitalize on upcoming opportunities in fiscal 2026 and beyond [9][36] - The company is exploring ways to enhance the Christmas Spectacular and improve per-show revenues through strategic pricing and partnerships [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for fiscal 2026, citing positive momentum across the business and expectations for solid growth in revenue and adjusted operating income [12][13] - The company is closely monitoring the macro environment but continues to see strong consumer demand, particularly for concerts and the Christmas Spectacular [44][45] Other Important Information - The company repurchased approximately $25 million of its Class A common stock during the quarter, with $45 million remaining under the current buyback authorization [12][29] - The cash component of arena license fees will be $45 million this fiscal year, growing at 3% annually through fiscal 2055 [6] Q&A Session Summary Question: Thoughts on the Christmas Spectacular's sell-through and pricing - Management noted strong demand for the Christmas Spectacular, expecting over 1 million guests and advanced ticket revenues pacing up double digits compared to last year [17][18] Question: Updates on concert bookings for the Garden - Management confirmed robust bookings, with more concerts booked for fiscal 2026 than held last year, and expressed confidence in increasing event numbers [21][22] Question: Progress on major residency acts for fiscal 2027 - Management indicated progress in finalizing a residency for next year, which could significantly enhance concert growth at the Garden [26][27] Question: Transitioning sponsorship business back in-house - Management confirmed the internal sales team is largely in place and optimistic about capitalizing on sponsorship opportunities [35][36] Question: Updates on Penn Station redevelopment - Management provided a timeline for redevelopment, emphasizing commitment to improving the area and collaboration with stakeholders [50] Question: Bookings growth by event type - Management expects growth driven by concerts, family shows, and sports, with a focus on improving financial results in family shows and modest growth in sports events [51][53]

Core Insights - Kimball Electronics, Inc. (KE) reported first-quarter fiscal 2026 non-GAAP earnings of 49 cents per share, exceeding the Zacks Consensus Estimate by 104.2% and up from 22 cents per share a year ago [1][9] - The company has consistently beaten earnings estimates over the past four quarters, with an average surprise of 23.7% [1] Revenue Performance - Kimball Electronics posted revenues of $365.6 million for the first quarter of fiscal 2026, surpassing the Zacks Consensus Estimate by 6.28%, but down 2.3% year over year from $374.26 million [2][9] - The medical vertical generated $101.6 million in revenues, accounting for 28% of total revenues, marking a 13% year-over-year increase driven by strong demand in various medical applications [3] - The automotive vertical contributed $164.4 million, representing 45% of total revenues, which is a 10% decline year over year due to normalization of demand and ongoing program transitions among OEM customers [4] - Revenues from the industrial vertical, excluding divested segments, were $99.6 million, making up 27% of total revenues, down 1% year over year, supported by steady demand across various industrial applications [5] Profitability Metrics - Gross profit for the quarter rose to $28.8 million, resulting in a gross margin of 7.9%, an increase of 160 basis points from the previous year [6] - Adjusted operating income reached $17.5 million, up 39.9% year over year, with an adjusted operating margin of 4.8%, expanding 140 basis points from 3.4% a year ago [6] - Adjusted net income was $12.25 million, reflecting a significant increase of 121.6% year over year [6] Balance Sheet and Cash Flow - At the end of the quarter, Kimball Electronics had cash and equivalents of $75.7 million, down from $88.8 million in June 2025, while debt decreased to $138 million, the lowest level in over three years [7] - The company generated $8.1 million in cash from operations [7] Guidance and Outlook - Kimball Electronics reiterated its fiscal 2026 revenue guidance, expecting a range between $1.35 billion and $1.45 billion, with the Zacks Consensus Estimate at $1.4 billion, indicating a year-over-year decline of 5.72% [8] - The company anticipates an adjusted operating margin between 4.0% and 4.25% for fiscal 2026 and capital expenditures in the range of $50-$60 million [8]

Core Insights - Ralph Lauren raised its full-year outlook due to strong performance, recording double-digit revenue growth across all geographic segments [1] Company Performance - The company experienced double-digit revenue growth in all geographic segments, indicating robust demand and effective market strategies [1]

Core Insights - Smith & Nephew reported Q3 results that align with expectations, supporting full-year guidance for revenue growth and trading margin [2] - Underlying revenue growth for the quarter was 5%, driven by momentum in Sports Medicine and Advanced Wound Management [3] - Orthopaedics growth showed trends similar to the previous quarter, with strong performance in Hips in the U.S. offsetting softer Knee sales [3] Revenue Performance - The strongest Q3 for core Replacements was recorded globally, with significant growth in Trauma and Extremities [3] - Excluding China, underlying revenue growth was 6.4%, indicating a balanced growth across geographies as headwinds in China begin to ease [4]

Core Insights - ACI Worldwide reported strong third-quarter and year-to-date results, indicating continued growth in its Payment Software and Biller segments [1] - The company raised its full-year 2025 outlook for revenue and adjusted EBITDA, reflecting positive momentum in its financial performance [1] - An updated share repurchase authorization was announced, signaling confidence in the company's future prospects [1] Financial Performance - The third-quarter results showed strong revenue growth, with significant increases in adjusted EBITDA and bookings [1] - The company’s performance in Q3 is characterized by continued positive momentum, as stated by CEO Thomas Warsop [1]

RT Bullpen (@BullpenFi)Bullpen is currently Top 5 in 30-Day Revenue across all @HyperliquidX Builder CodesUser growth: +180%Revenue growth: +239%Volume growth: +301%probably nothing. https://t.co/yY6Omm1JJZ ...

Financial Data and Key Metrics Changes - Tutor Perini reported a strong third-quarter revenue of $1.42 billion, representing a 31% year-over-year increase [16] - Operating cash flow reached $289 million for the quarter and $574 million for the first nine months of 2025, both setting new records [4][23] - Adjusted earnings per share (EPS) for the third quarter was $1.15, a significant improvement from an adjusted loss of $1.61 per share in the same quarter last year [8][22] - GAAP EPS was $0.07 for the third quarter, compared to a loss of $1.92 per share in the same quarter last year [9][21] Business Line Data and Key Metrics Changes - Civil segment revenue was $770 million, up 41% year-over-year, with operating income from construction operations at $99 million, a substantial improvement from a loss of $13 million last year [16][17] - Building segment revenue was $419 million, slightly down from last year, but operating income improved to $14 million from a loss of $4 million [16][18] - Specialty contractor segment revenue surged 124% to $226 million, with a return to profitability, reporting an income of $6 million compared to a loss of $57 million last year [16][19] Market Data and Key Metrics Changes - The company's backlog reached a record $21.6 billion, up 54% year-over-year, driven by $2 billion in new awards and contract adjustments in the third quarter [6][27] - The civil segment continues to perform at record levels, while the specialty contractor segment has shown significant recovery and profitability [8][19] Company Strategy and Development Direction - Tutor Perini aims to capitalize on favorable macroeconomic conditions and strong market demand for construction services, particularly in civil and building segments [5][10] - The company is focused on pursuing projects with favorable contractual terms and higher margins, emphasizing a selective approach to bidding [12] - Future bidding opportunities are expected to exceed $25 billion over the next 12 to 18 months, with significant projects primarily located in California, New York, and the Midwest [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's performance and raised guidance for adjusted EPS for 2025 to a range of $4-$4.20, up from previous guidance [13] - The outlook remains positive beyond 2025, with expectations for significantly higher adjusted EPS in 2026 and 2027 [14] - Management does not foresee significant impacts from government funding cuts or the recent federal government shutdown on major projects [15] Other Important Information - The company plans to continue building its cash position until it reaches a level suitable for initiating strategic capital allocation alternatives, such as dividends or share repurchase programs [5] - Total debt decreased by 23% to $413 million, with cash on hand exceeding total debt by $283 million [23] Q&A Session Summary Question: Can you give a little more color on specialty turning positive? - Management indicated that the specialty performance is driven by successful non-claim resolution work, leading to improved results [33] Question: Does the specialty revenue trend up from the Q3 level? - Management confirmed that specialty revenue is expected to increase as larger projects ramp up [34] Question: How many of the legacy disputes are remaining? - Management estimated about a dozen significant legacy disputes remain [35] Question: Is bidding activity staying robust? - Management affirmed that bidding activity remains strong across major geographies, particularly in New York and California [41] Question: Could you exit the fourth quarter at another record? - Management suggested that while new records may occur, the growth may be lumpier and not consistently increasing [49] Question: What is the outlook for building segment margins? - Management expects building segment margins to improve significantly by mid-2026 due to the mix of higher-margin projects [72] Question: What are the dynamics with government funding? - Management does not anticipate significant impacts from government funding changes, maintaining active dialogue with customers [74]

Core Insights - E.l.f. Beauty's acquisition of Rhode is projected to significantly boost annual sales by $200 million in the current fiscal year, highlighting Rhode as a key growth driver for E.l.f. [1][2] - The acquisition, finalized for $1 billion, is expected to generate $300 million in revenue annually after Rhode's launch in Sephora stores, marking the largest brand launch in Sephora's North American history [2][3] Financial Performance - E.l.f. reported a net income of $3 million (5 cents per share) for the quarter ending September 30, a decline from $19 million (33 cents per share) a year earlier, despite strong sales from Rhode and other channels [4] - Total sales increased to $344 million, reflecting a 14% rise from $301 million the previous year, although the company missed revenue estimates [4][9] - The company's gross margin fell by 1.65 percentage points due to increased tariff costs, leading to an 84% drop in net income [5][6] Future Outlook - E.l.f. anticipates full-year revenue between $1.55 billion and $1.57 billion, indicating an 18% to 20% growth, but below the $1.65 billion expected by analysts [7][8] - Rhode's contribution to sales is estimated to account for approximately 13% of the projected revenue, underscoring the strategic importance of the acquisition [8] - Adjusted earnings per share are expected to be between $2.80 and $2.85, significantly lower than the $3.58 forecasted by analysts [8]

Financial Data and Key Metrics Changes - The company reported record revenue of $82 million for Q3 2025, representing a 17% increase year-over-year [14] - Total revenues for the year-to-date period reached $237 million, indicating a 14% growth compared to the same period last year [17] - GAAP net income for Q3 was $8 million, down from $11.6 million in the prior year, while non-GAAP net income increased to $22.4 million from $15.4 million [18] Business Line Data and Key Metrics Changes - Tyvaso DPI generated $33 million in royalties, a 23% increase, and $26 million in manufacturing-related revenue [4] - Afrezza's net revenue rose 23% to $18.5 million, with a 31% increase in new prescriptions and a 27% increase in total prescriptions year-over-year [5][14] - V-Go contributed $3.8 million, down 19% year-over-year, consistent with the company's expectations as it no longer actively promotes the product [15] Market Data and Key Metrics Changes - Furoscix revenue reached $19.3 million in Q3 2025, with year-to-date revenue of $47.1 million, a 95% increase over the same period in 2024 [9] - The company anticipates significant market opportunities in heart failure and chronic kidney disease, with 2.1 million addressable heart failure episodes in the U.S. [10] Company Strategy and Development Direction - The acquisition of SC Pharmaceuticals is aimed at unlocking the potential of Furoscix and advancing inhaled bumetanide for fluid overload and heart failure [2][7] - The company is focused on expanding its footprint in cardiometabolic care and enhancing its commercial scale through the integration of SC Pharmaceuticals [6][7] - The strategy includes increasing the share of voice in cardiology and nephrology to raise awareness and drive adoption of Furoscix [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in clinical development programs and the potential for growth through various catalysts [3] - The company is preparing for the pediatric launch of Afrezza, with a focus on driving prescribing among top prescribers [6] - Management highlighted the importance of early intervention in heart failure care, aligning with upcoming changes in Medicare payment models [11] Other Important Information - The company has submitted a supplemental BLA for Afrezza, with a PDUFA date set for Q2 2026 [2] - The company utilized $133 million of its cash and investments to fund the acquisition of SC Pharmaceuticals and borrowed $325 million on a term loan facility [16] Q&A Session Summary Question: Thoughts on recent approvals from Furoscix competitors and pricing context - Management acknowledged awareness of competitors and emphasized product differentiation and lifecycle management as key focuses [28] Question: Timing for the Tyvaso bridging study in IPF - Management indicated that the bridging study could be similar to the BREEZE study, with communication to the FDA expected soon [34] Question: Integration process with SC Pharmaceuticals - Integration is progressing smoothly, with cultural similarities easing the process and key personnel already placed in leadership roles [36] Question: Peak sales opportunity for Furoscix - Management referenced analyst reports suggesting peak sales could exceed $500 million, with further guidance pending [45] Question: Impact of the Ready Flow Auto-Injector on unique prescribers - Management highlighted the potential for market expansion and increased awareness among cardiologists as key growth drivers [79]

Core Insights - Sportstech's revenue growth accelerated to 24% year-over-year (YoY) in the third quarter of 2025, up from 18% YoY in the second quarter [1] - The company expects revenue growth to surpass 30% YoY in the fourth quarter of 2025 [1] - Current foreign exchange (FX) rates indicate that Sportstech's last twelve months (LTM) revenue as of September 2025 would be approximately $58 million, with an LTM EBITDA of $6 million [1] - Interactive Strength Inc. (TRNR) confirmed that all parties are diligently working on completing the acquisition closing requirements for Sportstech [1] Revenue Performance - Sportstech reported third quarter 2025 revenue exceeding $13 million, reflecting a 24% YoY growth [1] - This growth represents an acceleration from the previous quarter's 18% YoY growth [1] Future Projections - The company anticipates that revenue growth will exceed 30% YoY in the upcoming fourth quarter [1] - Based on current FX rates, projected LTM revenue for Sportstech by September 2025 is approximately $58 million [1]